BFRG (Bullfrog AI Holdings) Valuation Rank

View and export this data going back to 2023. Start your Free Trial

What is Bullfrog AI Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Bullfrog AI Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of Bullfrog AI Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Bullfrog AI Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bullfrog AI Holdings Inc (NAS:BFRG) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

325 Ellington Boulevard, Unit 317, Gaithersburg, MD, USA, 20878

Website

https://www.bullfrogai.com

Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.

Executives

William Enright	director	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
R Don Elsey	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Dane R Saglio	officer: Chief Financial Officer
Jason David Hanson	director	8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Vininder Singh	director, 10 percent owner, officer: Chief Executive Officer	4 BLACK KETTLE COURT, BOYDS MD 20841